NCT05812326 is a single-center, open-label, completed phase 1/2 trial evaluating the safety and efficacy of PD-1 gene knockout anti-MUC1 CAR-T cells (AJMUC1) in patients with advanced MUC1-positive breast cancer [40]. Here, MUC1 is linked to breast cancer.